Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros

Base de dados
Tipo de documento
Assunto da revista
País de afiliação
Intervalo de ano de publicação
1.
J Drugs Dermatol ; 19(7): 719-724, 2020 Jul 01.
Artigo em Inglês | MEDLINE | ID: mdl-32726554

RESUMO

Background: There is currently an unmet need for the treatment of women with central centrifugal cicatricial alopecia (CCCA). Objective: To evaluate the safety and efficacy of Clobetasol propionate 0.05% emollient foam for the treatment of women with CCCA. Methods: Adult women of African descent that presented with clinical evidence of early CCCA were enrolled (N=30). Clobetasol propionate 0.05% emollient foam was applied daily in an open-label fashion. Safety and efficacy assessments were performed at weeks 2, 6, 12, and 14. Results: Subjects achieved substantial improvements in pruritus, pain, tenderness, erythema and scaling. Scalp biopsies revealed considerable improvements in severe inflammation and perifollicular edema. Overall, clobetasol propionate 0.05% emollient foam was well-tolerated. Limitations: This was a nonrandomized, open-label study. Enrollment was limited to subjects with clinically mild CCCA. Conclusion: Subjects with CCCA that applied topical clobetasol propionate 0.05% emollient foam to their scalp daily demonstrated continuous clinical improvement throughout the 14-week study. ClinicalTrials.gov Identifier: NCT01111981 J Drugs Dermatol. 2020;19(7): doi:10.36849/JDD.2020.5201.


Assuntos
Alopecia/tratamento farmacológico , Anti-Inflamatórios/uso terapêutico , Clobetasol/uso terapêutico , Emolientes/uso terapêutico , Administração Cutânea , Adulto , Idoso , Alopecia/patologia , Anti-Inflamatórios/administração & dosagem , Clobetasol/administração & dosagem , Emolientes/administração & dosagem , Feminino , Humanos , Pessoa de Meia-Idade , Índice de Gravidade de Doença , Resultado do Tratamento , Adulto Jovem
2.
J Drugs Dermatol ; 12(2): 217-9, 2013 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-23377397

RESUMO

Incidents of new-onset vitiligo attributed to infliximab therapy for rheumatoid arthritis and ulcerative colitis have been reported. Reported cases share a common theme in that symptoms manifested in close proximity to the initiation or significant dose increase of the medication. This case describes the presentation of infliximab-induced vitiligo in a patient using it for long-term treatment of stable pityriasis rubra pilaris. The patient was initiated and titrated to a stable dose of infliximab totaling 27 months' duration. He was able to achieve near-complete resolution of symptoms before developing depigmented patches consistent with vitiligo. Infliximab was discontinued. Tacrolimus 0.1% ointment and narrow-band ultraviolet B light successfully repigmented the patches. The association of discontinuing infliximab and resolution of vitiligo suggests infliximab had a role in this case. Though the mechanism of involvement is undetermined, infliximab may have induced an autoimmune process by paradoxically activating lymphocytes. Alternatively, infliximab antibodies may have led to the process by disrupting the normal balance of cytokines.


Assuntos
Anticorpos Monoclonais/efeitos adversos , Anticorpos Monoclonais/uso terapêutico , Antirreumáticos/efeitos adversos , Antirreumáticos/uso terapêutico , Pitiríase Rubra Pilar/complicações , Pitiríase Rubra Pilar/tratamento farmacológico , Vitiligo/induzido quimicamente , Artrite Reumatoide/complicações , Artrite Reumatoide/tratamento farmacológico , Diabetes Mellitus Tipo 2/complicações , Gota/complicações , Humanos , Imunossupressores/uso terapêutico , Infliximab , Masculino , Pessoa de Meia-Idade , Tacrolimo/uso terapêutico , Terapia Ultravioleta
3.
J Drugs Dermatol ; 11(2): 247-9, 2012 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-22270211

RESUMO

Acitretin, a metabolite of the aromatic retinoid etretinate, has been utilized successfully in the treatment of psoriasis since the late 1980s. Of the oral retinoids available, etretinate and acitretin are the most likely agents to induce various dose-dependent hair changes, but to our knowledge this is the first reported case of acitretin-induced poliosis. Additional cutaneous findings included skin atrophy and stickiness. Here we report a case of full body acitretin-induced poliosis with concurrent alopecia in a patient with psoriasis. A proposed mechanism for the poliosis is also presented here. Closer examination of retinoid-induced hair changes is needed in order to help physicians better counsel their patients regarding the adverse effects of acitretin and to expand the current knowledge on hair follicle biology.


Assuntos
Acitretina/efeitos adversos , Alopecia/induzido quimicamente , Alopecia/diagnóstico , Dermatopatias/induzido quimicamente , Dermatopatias/diagnóstico , Alopecia/complicações , Humanos , Masculino , Pessoa de Meia-Idade , Transtornos da Pigmentação/induzido quimicamente , Transtornos da Pigmentação/complicações , Transtornos da Pigmentação/diagnóstico , Dermatopatias/complicações
4.
Am J Dermatopathol ; 31(5): 487-9, 2009 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-19542928

RESUMO

Rosai-Dorfman disease or sinus histiocytosis with massive lymphadenopathy is a rare disease. A third of patients with this disease have extranodal involvement affecting the skin. Of these individuals, only around 3% will have purely cutaneous Rosai-Dorfman disease, which is limited to skin manifestations without systemic involvement. Cutaneous (localized) scleroderma or morphea, on the other hand, is a more common disease that most often affects women of all ages. Both conditions have unknown etiologies. Presented here is a case of a 60-year-old white woman with cutaneous Rosai-Dorfman disease and coexisting morphea. Representative biopsies from both areas were performed: one showing a dermal S-100+ histiocytic infiltrate with emperipolesis and the other showing a deep perivascular and interstitial plasma cell infiltrate with dermal sclerosis and loss of perieccrine fat. A laboratory and radiologic workup revealed no evidence of systemic involvement by either entity. The diagnosis of coexisting cutaneous Rosai-Dorfman disease and morphea was established. To our knowledge, this is the first report of these 2 entities found simultaneously in 1 patient.


Assuntos
Histiocitose Sinusal/complicações , Histiocitose Sinusal/patologia , Esclerodermia Localizada/complicações , Esclerodermia Localizada/patologia , Corticosteroides/uso terapêutico , Anti-Inflamatórios/uso terapêutico , Doença da Artéria Coronariana/complicações , Diabetes Mellitus Tipo 2 , Feminino , Histiocitose Sinusal/tratamento farmacológico , Humanos , Hipertensão/complicações , Imuno-Histoquímica , Pessoa de Meia-Idade , Esclerodermia Localizada/tratamento farmacológico , Esclerodermia Localizada/metabolismo , Triancinolona/uso terapêutico
5.
J Drugs Dermatol ; 8(6): 573-6, 2009 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-19537383

RESUMO

Sorafenib, a multitargeted kinase inhibitor used for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinomas, received FDA approval in 2005. Since its introduction to the market, there have been various dermatologic side effects reported in the literature, the most well known being hand-foot skin reaction. This article presents a case of an atypical localized cutaneous eruption with an unusual course and protracted resolution time associated with sorafenib therapy.


Assuntos
Acantólise/induzido quimicamente , Benzenossulfonatos/efeitos adversos , Toxidermias/etiologia , Ceratose/induzido quimicamente , Inibidores de Proteínas Quinases/efeitos adversos , Piridinas/efeitos adversos , Benzenossulfonatos/administração & dosagem , Carcinoma Hepatocelular/complicações , Carcinoma Hepatocelular/tratamento farmacológico , Diabetes Mellitus , Hepatite B/complicações , Humanos , Neoplasias Hepáticas/complicações , Neoplasias Hepáticas/tratamento farmacológico , Masculino , Pessoa de Meia-Idade , Niacinamida/análogos & derivados , Compostos de Fenilureia , Inibidores de Proteínas Quinases/administração & dosagem , Piridinas/administração & dosagem , Sorafenibe
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa